Drug Profile

HRN 001

Alternative Names: HRN-001

Latest Information Update: 03 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Harness Therapeutics
Class RNA
Mechanism of Action FAN1 protein expression modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Huntington's disease

Most Recent Events

27 Jan 2025 Pharmacodynamics data from a preclinical trial in Huntington’s disease released by Harness Therapeutics
27 Jan 2025 Harness Therapeutics plans a phase I/II trial for Huntington's disease (Parenteral) in 2026
30 May 2024 Harness Therapeutics plans a clinical trial for Huntington's disease

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com